Brief: 9 Meters Biopharma Announces Preliminary Results From Phase 2 Study Of Vurolenatide In Short Bowel Syndrome

9 Meters Biopharma

30/06/2022 12:12

June 30 (Reuters) - 9 Meters Biopharma Inc  NMTR.O :
    * 9 METERS BIOPHARMA INC - ANNOUNCES POSITIVE PRELIMINARY
RESULTS
FROM PHASE 2 STUDY OF VUROLENATIDE IN SHORT BOWEL SYNDROME
    * 9 METERS BIOPHARMA INC - VUROLENATIDE WAS GENERALLY WELL
TOLERATED WITH NO ADVERSE EVENTS LEADING TO EARLY STUDY
WITHDRAWAL
    * 9 METERS BIOPHARMA - END-OF-PHASE 2 MEETING WITH FDA
SCHEDULED
FOR MID-THIRD QUARTER
    * 9 METERS BIOPHARMA - NO ADVERSE EVENTS LEADING TO EARLY
STUDY
WITHDRAWAL

Source text for Eikon: [https://bit.ly/3udSSVT]
Further company coverage:  NMTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))